**BIOLOGICAL ACTIVITY:**

Rivastigmine tartrate, an cholinesterase inhibitor (IC50 = 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesterase.

IC50 value: 5.5 uM

Target: AChE

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and dementia due to Parkinson’s disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug–drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.

**References:**


**Caution:** Product has not been fully validated for medical applications. For research use only.